6-羟甲基吡啶-2-甲酸乙酯 | 41337-81-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-羟甲基吡啶-2-甲酸乙酯
• 中文别名: 6-羟基甲基-吡啶-2-羧酸乙酯
• 英文名称: ethyl 6-(hydroxymethyl)pyridine-2-carboxylate
• 英文别名: 6-(hydroxymethyl)-2-pyridinecarboxylic acid ethyl ester；6-(hydroxymethyl)pyridine-2-carboxylic acid ethyl ester；6-hydroxymethylpyridine-2-carboxylic acid ethyl ester；6-Hydroxymethyl-pyridin-2-carbonsaeure ethylester；ethyl 6-(hydroxymethyl)-2-pyridinecarboxylate；ethyl 6-hydroxymethyl-2-pyridinecarboxylate
• CAS: 41337-81-9
• 化学式: C₉H₁₁NO₃
• mdl: MFCD09750009
• 分子量: 181.191
• InChiKey: CDFOARSBQKJGNL-UHFFFAOYSA-N

物化性质

• 沸点：
  337.1±32.0 °C(Predicted)
• 密度：
  1.200±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 安全说明：
  S24/25,S36/37
• 危险类别码：
  R20/21/22
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 6-(hydroxymethyl)pyridine-2-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 6-(hydroxymethyl)pyridine-2-carboxylate
CAS number: 41337-81-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H11NO3
Molecular weight: 181.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-羟甲基吡啶-2-甲酸乙酯 在 乙基溴化镁 、 三氧化硫吡啶 、 二甲基亚砜 作用下， 以 二氯甲烷 为溶剂， 生成 ethyl 6-[(5-chloro-2-hydroxyphenyl)hydroxymethyl]-2-pyridinecarboxylate
  参考文献：
  名称：

  Development of an in vivo active, dual EP1 and EP3 selective antagonist based on a novel acyl sulfonamide bioisostere

  摘要：

  Recent preclinical studies demonstrate a role for the prostaglandin E-2 (PGE(2)) subtype 1 (EP1) receptor in mediating, at least in part, the pathophysiology of hypertension and diabetes mellitus. A series of amide and N-acylsulfonamide analogs of a previously described picolinic acid-based human EP1 receptor antagonist (7) were prepared. Each analog had improved selectivity at the mouse EP1 receptor over the mouse thromboxane receptor (TP). A subset of analogs gained affinity for the mouse PGE2 subtype 3 (EP3) receptor, another potential therapeutic target. One analog (17) possessed equal selectivity for EP1 and EP3, displayed a sufficient in vivo residence time in mice, and lacked the potential for acyl glucuronide formation common to compound 7. Treatment of mice with 17 significantly attenuated the vasopressor activity resulting from an acute infusion of EP1 and EP3 receptor agonists. Compound 17 represents a potentially novel therapeutic in the treatment of hypertension and diabetes mellitus. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.046
• 作为产物：
  描述：

  吡啶-2,6-二甲酸 在 硫酸 作用下， 反应 22.0h， 生成 6-羟甲基吡啶-2-甲酸乙酯
  参考文献：
  名称：

  基于 GdIII 的自旋标记在通过零场分裂优化线宽减少的极限

  摘要：

  电子顺磁共振谱中非常窄的中心线和非常弱的零场分裂 (ZFS) 使 [Gd III (NO3Pic)] ([Gd III (TPATCN)]) 成为自旋标记开发的一个有吸引力的起点。为了在用能够实现生物共轭的取代基对其进行修饰时保留该母体复合物的窄线，发现在吡啶甲酸酯部分具有某种远程官能团作为取代基的烷基非常合适，因为 ZFS 保持弱，即使三重轴对称是破碎的。ZFS 太弱以至于超精细耦合和/或g-值变化显着决定了生物分子质子化时 Q 波段和更高场的线宽，这是标准情况，以及 W 波段和完全氘化环境中质子化复合物的更高场。显然，[NDSE-{Gd III (NO3Pic)}]，一种靶向肽中半胱氨酸的自旋标记，通过 ZFS 最小化处于线宽变窄的极限。标记反应具有高度化学选择性，并且应用于具有两个半胱氨酸单元的聚脯氨酸，在 7 °C 和 pH 7.8 下不超过一分钟。随后的二硫化物加扰非常缓慢，因此

  DOI：

  10.1021/acs.inorgchem.2c03531

文献信息

• [EN] COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK<br/>[FR] COMBINAISONS D'INHIBITEURS DE L'IRAK4 À L'AIDE D'INHIBITEURS DE LA BTK
  申请人：BAYER PHARMA AG

  公开号：WO2016174183A1

  公开（公告）日：2016-11-03

  The present application relates to novel combinations of at least two components, component A and component B: · component A is an IRAK4-inhibiting compound of the formula (I) as defined herein, or a diastereomer, an enantiomer, a metabolite, a salt, a solvate or a solvate of a salt thereof; · component B is a BTK-inhibiting compound, or a pharmaceutically acceptable salt thereof; and, optionally, · one or more components C which are pharmaceutical products; in which one or two of the above-defined compounds A and B are optionally present in pharmaceutical formulations ready for simultaneous, separate or sequential administration, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis, lymphoma, macular degeneration, COPD, neoplastic disorders and psoriasis.

  本申请涉及至少两种组分的新型组合，组分A和组分B：·组分A是根据本文所定义的式(I)的IRAK4抑制化合物，或其对映体、对映异构体、代谢物、盐、溶剂合物或其盐的溶剂合物；·组分B是BTK抑制化合物，或其药学上可接受的盐；以及，可选地，·一种或多种组分C，它们是药用产品；其中上述定义的化合物A和B中的一种或两种可选择地存在于用于治疗和/或预防疾病的制剂中，准备用于同时、分开或顺序给药，用于治疗和/或预防疾病，以及用于生产用于治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防子宫内膜异位症、淋巴瘤、黄斑变性、慢性阻塞性肺病、肿瘤性疾病和牛皮癣。
• Synthesis and binding properties of guanidinium biscarboxylates
  作者：Andreas Späth、Janina Gonschor、Burkhard König

  DOI：10.1007/s00706-011-0660-x

  日期：2011.12

  AbstractThe ammonium ion binding site of the enzyme glutaminase HisF inspired us to design guanidinium biscarboxylates as potential self-organized ionophores in molecular recognition. The syntheses of the title compounds based on aliphatic and aromatic building blocks, along with a general method for the preparation of δ-aminoethoxyacetic acids, are presented in this work. Investigation of the binding

  摘要谷氨酰胺酶HisF的铵离子结合位点启发我们设计双羧酸胍盐作为分子识别中潜在的自组织离子载体。这项工作介绍了基于脂肪族和芳香族结构单元的标题化合物的合成，以及制备δ-氨基乙氧基乙酸的一般方法。对标题化合物在二甲亚砜（DMSO）和甲醇溶液中的结合性能的研究表明，没有铵离子亲和力，但胍基部分与乙酸根离子相互作用。 图形概要
• NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20190071432A1

  公开（公告）日：2019-03-07

  The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

  本申请涉及新型取代吲唑并[1,2,3]三唑化合物，其制备方法，其单独或组合用于治疗和/或预防疾病的用途，以及其用于制备用于治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防子宫内膜异位症及其相关疼痛和其他子宫内膜异位症症状，如经痛、性交痛、排尿困难和排便困难，淋巴瘤、类风湿关节炎、脊柱关节炎（特别是银屑病性脊柱关节炎和贝赫切夫病）、红斑狼疮、多发性硬化、黄斑变性、慢性阻塞性肺病、痛风、脂肪肝疾病、胰岛素抵抗、肿瘤性疾病和银屑病。
• [EN] NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES<br/>[FR] NOUVELLES IMIDAZO[1,5-A]PYRIDINES SUBSTITUÉES EN 5ÈME OU 8ÈME POSITION EN TANT QU'INDOLEAMINE ET/OU TRYPTOPHANE 2,3-DIOXYGÉNASES
  申请人：BEIGENE LTD

  公开号：WO2016161960A1

  公开（公告）日：2016-10-13

  Disclosed herein are 5 or 8-substituted imidazo[l,5-a]pyridines and pharmaceutical compositions comprising at least one such 5 or 8-substituted imidazo[l,5-a]pyridines, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain 5 or 8- substituted imidazo[l,5-a]pyridines that can be useful for inhibiting indoleamine 2,3- dioxygenase and/or tryptophane 2,3-dioxygenase and for treating diseases or disorders mediated thereby.

  本文披露了5或8-取代咪唑[1,5-a]吡啶和包含至少一种此类5或8-取代咪唑[1,5-a]吡啶的药物组合物，以及其制备方法和在治疗中的用途。本文披露了某些5或8-取代咪唑[1,5-a]吡啶，可用于抑制吲哚胺2,3-二氧化酶和/或色氨酸2,3-二氧化酶，并用于治疗由此介导的疾病或疾病。
• 两亲性Tb(Ⅲ)配合物及其制备方法以及荧光纳 米纤维的制备方法和应用
  申请人：陕西师范大学

  公开号：CN104447935B

  公开（公告）日：2016-05-11

  两亲性Tb(Ⅲ)配合物及其制备方法以及荧光纳米纤维的制备方法和应用，基于胆固醇分子的刚性骨架、生物相容性以及自组装等特点，设计制备了含胆固醇结构单元和双吡啶羧酸的两亲性Tb(Ⅲ)配合物，组装了基于此配合物的超分子荧光纳米纤维，研究了该荧光纳米纤维与金精三羧酸的作用机理，利用金精三羧酸与Tb(Ⅲ)离子间的协同络合以及能量转移过程实现了对金精三羧酸的高效传感。本发明所涉及的化学反应条件温和易实现，荧光纳米纤维的制备方法简便易操作，且所得纳米纤维尺寸均一，检测金精三羧酸的灵敏度高，选择性好，有望在研究金精三羧酸的药理过程中获得应用。